Hint mode is switched on Switch off
For swift navigation between sections

Novavax
LEI 529900J4GJHPEPQ23205

PDF download

Choose all Reset all
Download Cancel
Organization name
Novavax, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
251 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is a public company that trades under the symbol "NVAX"

Awards

News

15/01/2026 Novavax: Entry Into Material Definitive Agreements
17/10/2025 Novavax: Entry Into A Material Definitive Agreement, Material Impairments, Other Events, Financial Statements And Exhibits
27/08/2025 Novavax: Regulation Fd Information, Other Events, Financial Statements And Exhibits
27/08/2025 Novavax: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits
20/08/2025 Novavax: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    529900J4GJHPEPQ23205
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001000694
  • EIN
    22-2816046
Registration is required to get access.